Effect of inhibitor of poly (ADP-ribose) polymerase in blood lymphocyte cultures of untreated leprosy patients

Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

“…Studies with early generation PARP inhibitors (e.g. 3-aminobenzamide) produced equivocal results, as in some studies, sister chromatid exchange rates and malignant transformations were reduced (Borek et al, 1984), while in other studies, they remained unaffected (D'Souza et al, 1992), and in yet other studies, increases were reported (Shiraishi et al, 1983;Schwartz et al, 1984;D'Souza et al, 1992). In line with the concept that PARP1 deficiency does not equal PARP catalytic inhibition (as already discussed above), Smulson and colleagues compared the tetraploidy inducing potential of PARP1 deficiency with GPI 6150 and found that while PARP1 deficiency increased the percentage of a genetically unstable tetraploid cell population in fibroblasts, the PARP inhibitor (20 μM, 3 weeks of continuous exposure) did not (Simbulan-Rosenthal et al, 2001).…”